JENNIFER PENNE: Open Payments
NPI 1497968101 · FAYETTEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,105 in 115 payments from 13 companies in 2025. Trend: 2023 $1,993 · 2024 $2,720 · 2025 $2,105
Food & beverage: $2,105
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 36 | $428 |
| ABBVIE INC. | 21 | $343 |
| Vanda Pharmaceuticals Inc. | 11 | $332 |
| Neurocrine BioSciences, Inc. | 8 | $172 |
| Axsome Therapeutics, Inc. | 4 | $158 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| Supernus Pharmaceuticals, Inc. | 1 | $119 |
| Corium, LLC | 10 | $105 |
| E.R. Squibb & Sons, L.L.C. | 5 | $92 |
| Lundbeck LLC | 5 | $89 |
Products named: CAPLYTA, VRAYLAR, FANAPT, INGREZZA, Auvelity, REXULTI, AUSTEDO XR, Qelbree.
Industry payments across AR — which companies pay providers there.
